1.8
약물-수용체 상호작용은 약물에 의한 수용체 결합을 설명하지만 모든 약물-수용체 상호작용이 활성화 및 조직 반응을 초래하는 것은 아닙니다. 예를 들어, 작용제의 결합은 수용체를 활성화하여 세포 반응을 생성하는 반면, 길항제는 활성화를 일으키지 않고 수용체에 결합합니다.
…
약물은 구조적 변화를 유도하거나 효과기 분자를 모집하여 세포 반응을 생성함으로써 수용체를 활성화합니다. 그러나 모든 약물이 결합 시 표적이나 수용체를 활성화하는 것은 아닙니다.
약물 결합은 수용체에 대한 약물의 친화력에 따라 다릅니다. 낮은 농도에서도 친화성이 높은 약물은 최대 수용체 점유를 위해 내인성 리간드와 경쟁합니다.
약물의 효능은 세포 반응을 유도하는 능력을 결정합니다. 약물은 친화력과 효능에 따라 작용제, 부분 작용제 또는 길항제로 분류됩니다.
작용제는 수용체를 활성화하여 최대 반응을 이끌어냅니다. 작용제는 수용체의 활성을 증가시키기 위해 내인성 리간드 결합 부위 또는 별도의 알로스테릭 부위에 결합할 수 있습니다. 수용체의 완전한 점유가 없어도 작용제의 효능은 거의 100%로 유지됩니다.
부분 작용제는 중간 효능을 가지며 100% 수용체 점유에서도 최대 이하의 반응만 생성할 수 있습니다.
마지막으로, 길항제는 수용체와 결합하고 비활성화하기 위해 내인성 리간드와 경쟁합니다. 따라서 길항제는 효능이 무시할 수 있을 정도로 미미하며 반응을 일으키지 않습니다.
View the full transcript and gain access to JoVE Core videos
Q1: What is the difference between drug affinity and drug efficacy?
Drug affinity is the ability of a drug to bind to its receptor, determining how readily it occupies receptor sites even at low concentrations. Efficacy is the drug's ability to activate the receptor and elicit a cellular response. High-affinity drugs compete effectively with endogenous ligands for receptor occupancy, while efficacy determines whether that binding produces a maximal, submaximal, or negligible response.
Q2: How do agonists activate receptors to produce a cellular response?
Agonists activate receptors by inducing conformational changes or recruiting effector molecules that generate a cellular response. They can bind to the endogenous ligand binding site or a separate allosteric site to increase receptor activity. Agonists have high affinity and nearly 100% efficacy, producing maximal responses even without total receptor occupancy.
Q3: Why do partial agonists produce submaximal responses despite full receptor occupancy?
Partial agonists have intermediate efficacy, meaning they cannot fully activate receptors even when bound to all available receptor sites. Unlike agonists with nearly 100% efficacy, partial agonists are intrinsically limited in their ability to generate a cellular response. This reduced efficacy results in submaximal tissue responses regardless of complete receptor occupancy.
Q4: What mechanism allows antagonists to block drug responses?
Antagonists compete with endogenous ligands and agonists for receptor binding sites, stabilizing the receptor in an inactive state. They have negligible efficacy and do not produce a response themselves. By occupying receptors, antagonists prevent agonists from binding and activating the receptor, effectively blocking the cellular response.
Q5: How do allosteric antagonists differ from pharmacologic antagonists?
Pharmacologic antagonists compete directly with other molecules for the same receptor binding site and stabilize the receptor in an inactive state. Allosteric antagonists bind to separate sites on the receptor and change the affinity and efficacy of agonists without competing for the primary binding site. Both reduce receptor activation but through distinct mechanisms.
Q6: Why is understanding drug-receptor binding essential for predicting drug effects?
Drug-receptor interactions determine whether a drug activates or inactivates its target, directly influencing tissue response. The drug's affinity, efficacy, and binding mechanism—whether at the agonist site or allosteric site—collectively determine its pharmacological effect. Understanding these interactions is critical for predicting how factors affecting drug response will influence therapeutic outcomes.
Q7: What determines whether a drug will be classified as an agonist, partial agonist, or antagonist?
Drug classification depends on two parameters: affinity and efficacy. Agonists have high affinity and high efficacy, producing maximal responses. Partial agonists have high affinity but intermediate efficacy, producing submaximal responses. Antagonists have variable affinity but negligible efficacy, producing no response. These properties determine the drug's functional effect on tissue.